Pulmatrix, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulmatrix, Inc. on December 9, 2015, reporting events that occurred on December 8, 2015. The filing addresses significant changes to the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Director Departure: David Maki resigned as a member of the Board of Directors, effective December 8, 2015. The resignation was not in connection with any disagreement regarding the Company's operations, policies, or practices.
- Director Appointment: Mark Iwicki was appointed as Chairman of the Board and a Class III director, effective December 8, 2015. His term expires at the next annual meeting of stockholders.
- Committee Assignments: Mr. Iwicki was appointed to the Audit Committee and the Compensation Committee.
- Compensatory Arrangement: Mr. Iwicki was granted a stock option to purchase 73,481 shares of common stock. The exercise price equals the fair market value on the grant date. The option has a ten-year term, with 25% vesting on the first anniversary and the remainder vesting monthly over the subsequent 36 months, contingent on continued service.
Outlook, Risks, and Management Commentary
Management highlighted Mr. Iwicki's background, noting over 25 years of experience as a biopharmaceutical industry leader. He currently serves as Chairman and CEO of Kala Pharmaceuticals and has previously held executive roles at Civitas Therapeutics, Blend Therapeutics, Sunovion Pharmaceuticals, Novartis, and Merck. The filing incorporates a press release regarding the appointment by reference but does not provide specific forward-looking guidance, risk factors, or contingencies related to the Company's business operations.
Key Facts for Investor Verification
- Confirm the effective date of David Maki's resignation and Mark Iwicki's appointment (December 8, 2015).
- Verify the terms of the stock option granted to Mr. Iwicki (73,481 shares, 10-year term, specific vesting schedule).
- Review the attached press release (Exhibit 99.1) for additional context on the Board's strategic direction.
- Note that this filing contains no financial data; refer to the most recent 10-K or 10-Q for financial metrics.